{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:08:01Z","timestamp":1782925681426,"version":"3.54.5"},"reference-count":143,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.clindermatol.2011.08.032","type":"journal-article","created":{"date-parts":[[2011,10,20]],"date-time":"2011-10-20T05:39:48Z","timestamp":1319089188000},"page":"587-601","source":"Crossref","is-referenced-by-count":19,"title":["Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts"],"prefix":"10.1016","volume":"29","author":[{"given":"Jennifer Nam","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2011.08.032_bb0005","series-title":"Cancer Facts & Figures\u20132010","author":"American Cancer Society","year":"2010"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0010","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jaad.2008.05.018","article-title":"Toxic erythema of chemotherapy: a useful clinical term","volume":"59","author":"Bolognia","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0015","first-page":"327","article-title":"Targeting epidermal growth factor receptor signaling: early results and future trends in oncology","volume":"35","author":"Lage","year":"2003","journal-title":"Ann Med"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0020","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrd1066","article-title":"Issues and progress with protein kinase inhibitors for cancer treatment","volume":"2","author":"Dancey","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0025","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000112795","article-title":"Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results","volume":"72","author":"Boone","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11523-009-0114-0","article-title":"Skin toxicities associated with epidermal growth factor receptor inhibitors","volume":"4","author":"Li","year":"2009","journal-title":"Target Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0040","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1365-2133.2006.07452.x","article-title":"The PRIDE (Papulopustules and\/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome","volume":"155","author":"Lacouture","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0045","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"Agero","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1634\/theoncologist.10-5-345","article-title":"HER1\/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1\/EGFR inhibitor rash management forum","volume":"10","author":"Perez-Soler","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0055","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.20.1.110","article-title":"Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition","volume":"20","author":"Albanell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0060","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1046\/j.1365-2133.2002.04864.x","article-title":"Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor","volume":"147","author":"Van Doorn","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0065","first-page":"1229","article-title":"Cutaneous reactions to epidermal growth factor receptor inhibitors","volume":"9","author":"Pomerantz","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0070","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1634\/theoncologist.2010-0063","article-title":"Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions","volume":"15","author":"Amitay-Laish","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0075","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jnci\/djp439","article-title":"Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy","volume":"102","author":"Eilers","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0080","first-page":"46","article-title":"Erlotinib-induced florid acneiform rash complicated by extensive impetiginization","volume":"33","author":"Kardaun","year":"2008","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0085","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1365-4632.2008.03691.x","article-title":"How important is the pus culture obtained from epithelial growth factor receptor (EGFR) inhibitors' associated rash?","volume":"47","author":"Cholongitas","year":"2008","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0090","unstructured":"Lacouture ME. The growing importance of skin toxicity in EGFR inhibitor therapy. Oncology (Williston Park) 2009;23:194, 6."},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0095","first-page":"338","article-title":"Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer","volume":"10","author":"Li","year":"2009","journal-title":"JOP"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0100","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0105","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0110","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/cncr.22915","article-title":"Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer","volume":"110","author":"Hecht","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0115","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0120","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0125","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10549-008-0020-7","article-title":"Analysis of dermatologic events in patients with cancer treated with lapatinib","volume":"114","author":"Lacouture","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000285776","article-title":"Safety profile and clinical recommendations for the use of lapatinib","volume":"5","author":"Chatsiproios","year":"2010","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0135","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.23621","article-title":"Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)","volume":"113","author":"Jatoi","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0140","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0145","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Available at: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Published June 14, 2010."},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0150","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00520-009-0744-x","article-title":"A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group","volume":"18","author":"Lacouture","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0155","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0160","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining?","volume":"23","author":"Perez-Soler","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0165","first-page":"34","article-title":"Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae","volume":"21","author":"Wagner","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0170","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1002\/cncr.25090","article-title":"Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life","volume":"116","author":"Joshi","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0175","first-page":"186","article-title":"Toward evidence-based management of the dermatologic effects of EGFR inhibitors","volume":"23","author":"LoRusso","year":"2009","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0180","first-page":"236","article-title":"The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors","volume":"4","author":"Lacouture","year":"2006","journal-title":"J Support Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0185","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0190","article-title":"Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB)","author":"Jatoi","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0195","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1634\/theoncologist.12-5-610","article-title":"Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management","volume":"12","author":"Lynch","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0200","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1188\/08.CJON.283-290","article-title":"An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors","volume":"12","author":"Eaby","year":"2008","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0205","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3747\/co.v16i1.361","article-title":"Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations","volume":"16","author":"Melosky","year":"2009","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0210","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1188\/08.ONF.103-111","article-title":"Clinical approaches to minimize rash associated with EGFR inhibitors","volume":"35","author":"Oishi","year":"2008","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0215","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1610-0387.2005.05058.x","article-title":"The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies","volume":"3","author":"Segaert","year":"2005","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0220","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0190-9622(80)80074-0","article-title":"The treatment of severe cystic acne with 13-cis-retinoic acid. Evaluation of sebum production and the clinical response in a multiple-dose trial","volume":"3","author":"Farrell","year":"1980","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0225","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0190-9622(82)70051-9","article-title":"The effects of retinoids on neutrophil functions in vitro","volume":"6","author":"Camisa","year":"1982","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0230","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaad.2006.11.004","article-title":"Epidermal growth factor receptor inhibitors: a new era of drug reactions in a new era of cancer therapy","volume":"56","author":"Cowen","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0235","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaad.2006.06.046","article-title":"Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy","volume":"56","author":"DeWitt","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0240","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2133.2005.06835.x","article-title":"Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy","volume":"153","author":"Gutzmer","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0245","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2340\/00015555-0330","article-title":"Cetuximab-induced acneiform eruption and the response to isotretinoin","volume":"88","author":"Vezzoli","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0250","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.144.7.949","article-title":"Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects","volume":"144","author":"Pomerantz","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0255","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1067\/mjd.2002.124621","article-title":"Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody","volume":"47","author":"Boucher","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0260","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0265","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaad.2008.01.001","article-title":"Chemotherapeutic agents and the skin: an update","volume":"58","author":"Heidary","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0270","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0275","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2133.2005.07010.x","article-title":"Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab","volume":"154","author":"Shu","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0280","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/annonc\/mdi300","article-title":"Trichomegaly of the eyelashes following treatment with cetuximab","volume":"16","author":"Bouche","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0285","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/02841860310006038","article-title":"Epidermal growth factor receptor inhibition induces trichomegaly","volume":"42","author":"Dueland","year":"2003","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0290","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/IOP.0b013e31802d9802","article-title":"Erlotinib-associated trichomegaly","volume":"23","author":"Lane","year":"2007","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0295","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1002\/j.1460-2075.1995.tb00206.x","article-title":"Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure","volume":"14","author":"Murillas","year":"1995","journal-title":"EMBO J"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0300","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2002.03.038","article-title":"Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial","volume":"20","author":"Herbst","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0305","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck","volume":"22","author":"Soulieres","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0310","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.2005.04.057","article-title":"Practical management of patients with non-small-cell lung cancer treated with gefitinib","volume":"23","author":"Shah","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0315","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3816\/CLC.2003.n.016","article-title":"Dermatologic side effects associated with gefitinib therapy: clinical experience and management","volume":"4","author":"Herbst","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0320","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/jnci\/dji104","article-title":"Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient","volume":"97","author":"Tonini","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0325","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.clinthera.2005.06.003","article-title":"Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer","volume":"27","author":"Wong","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0330","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.12-5-577","article-title":"FDA drug approval summary: panitumumab (Vectibix)","volume":"12","author":"Giusti","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0335","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2002.10.112","article-title":"ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial","volume":"20","author":"Ranson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0340","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1158\/1078-0432.CCR-04-0189","article-title":"Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer","volume":"10","author":"Park","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0345","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-4632.2005.02185.x","article-title":"Purpuric drug eruption possibly due to gefinitib (Iressa)","volume":"44","author":"Kurokawa","year":"2005","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0350","first-page":"22","article-title":"Necrolytic migratory erythema (glucagenoma)-like skin lesions induced by EGF-receptor inhibition","volume":"133","author":"Trojan","year":"2003","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0355","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/00015550410024634","article-title":"Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor","volume":"84","author":"Zorzou","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0360","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000092836","article-title":"Grover's disease induced by cetuximab","volume":"213","author":"Tscharner","year":"2006","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0365","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1592\/phco.27.8.1125","article-title":"Sorafenib and sunitinib: novel targeted therapies for renal cell cancer","volume":"27","author":"Grandinetti","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0370","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0375","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1665-2681(19)31582-0","article-title":"Advanced hepatocellular carcinoma. Review of targeted molecular drugs","volume":"10","author":"Alves","year":"2011","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0380","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0385","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0390","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0395","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0400","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290.x","article-title":"Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"161","author":"Lee","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0405","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3816\/CGC.2009.n.003","article-title":"Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib","volume":"7","author":"Dubauskas","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0410","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2230.2006.02223.x","article-title":"Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor","volume":"31","author":"Lacouture","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0415","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0420","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaad.2008.06.034","article-title":"Dermatologic symptoms associated with the multikinase inhibitor sorafenib","volume":"60","author":"Robert","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0425","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.annder.2008.04.016","article-title":"Eruptive nevi associated with sorafenib treatment","volume":"135","author":"Bennani-Lahlou","year":"2008","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0430","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archderm.144.6.820","article-title":"Sorafenib-induced eruptive melanocytic lesions","volume":"144","author":"Kong","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0435","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/SMJ.0b013e31802f01a9","article-title":"Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma","volume":"100","author":"Dasanu","year":"2007","journal-title":"South Med J"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0440","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3816\/CGC.2009.n.002","article-title":"Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis","volume":"7","author":"Chu","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0445","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/archderm.144.7.886","article-title":"Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor","volume":"144","author":"Autier","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0450","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","article-title":"Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy","volume":"158","author":"Yang","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0455","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/annonc\/mdi204","article-title":"Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?","volume":"16","author":"Jacobi","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0460","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1592\/phco.30.1.52","article-title":"Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction","volume":"30","author":"Jain","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"18S","key":"10.1016\/j.clindermatol.2011.08.032_bb0465","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/jco.2006.24.18_suppl.4594","article-title":"Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: update of a multicenter phase II trial. 2006 ASCO Annual Meeting Proceedings Part I","volume":"24","author":"Thompson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0470","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1634\/theoncologist.2008-0237","article-title":"Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs)","volume":"14","author":"Anderson","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0475","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1610-0387.2010.07449.x","article-title":"The hand-foot-syndrome associated with medical tumor therapy\u2014classification and management","volume":"8","author":"Degen","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0480","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0190-9622(91)70073-B","article-title":"Chemotherapy-induced acral erythema","volume":"24","author":"Baack","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0485","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/archderm.131.3.364","article-title":"Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur","volume":"131","author":"Jucgla","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0490","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2340\/00015555778081","article-title":"Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with Tegafur","volume":"77","author":"Rios-Buceta","year":"1997","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0495","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/annonc\/mdl477","article-title":"Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome)","volume":"18","author":"Lorusso","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0500","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.breast.2005.07.007","article-title":"Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction","volume":"15","author":"Kara","year":"2006","journal-title":"Breast"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0505","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1743-7563.2010.01311.x","article-title":"Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia","volume":"6","author":"Chalermchai","year":"2010","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0510","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1200\/JCO.2005.15.651","article-title":"Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand","volume":"23","author":"Scotte","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0515","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/cncr.23333","article-title":"Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot","volume":"112","author":"Scotte","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0520","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ygyno.2007.10.021","article-title":"Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling","volume":"108","author":"Mangili","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0525","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaad.2006.10.032","article-title":"Keratoacanthomas associated with sorafenib therapy","volume":"56","author":"Kong","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0530","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archderm.144.6.779","article-title":"Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib","volume":"144","author":"Hong","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0535","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jaad.2008.10.043","article-title":"The histologic spectrum of epithelial neoplasms induced by sorafenib","volume":"61","author":"Kwon","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0540","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1200\/JCO.2009.23.4823","article-title":"Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib","volume":"27","author":"Arnault","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0545","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1111\/j.1524-4725.2009.01289.x","article-title":"Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors","volume":"35","author":"Smith","year":"2009","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0550","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1001\/archdermatol.2010.395","article-title":"Invasive squamous cell carcinoma and sorafenib in a black patient","volume":"147","author":"Donaldson","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0555","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/CCO.0b013e3283436e8c","article-title":"RAF inhibition and induction of cutaneous squamous cell carcinoma","volume":"23","author":"Robert","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0560","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1755-148X.2010.00763.x","article-title":"PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas","volume":"23","author":"Lee","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0565","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0570","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0575","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0580","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.3513","article-title":"A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors","volume":"27","author":"Schwartz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0585","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.8503","article-title":"Phase I\/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors","volume":"28","author":"Kefford","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0590","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0595","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0600","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0605","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1001\/archderm.122.9.1023","article-title":"Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation","volume":"122","author":"Crider","year":"1986","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0610","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/archderm.121.10.1240b","article-title":"Cytarabine-induced palmar-plantar erythema","volume":"121","author":"Walker","year":"1985","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0615","doi-asserted-by":"crossref","first-page":"798","DOI":"10.7326\/0003-4819-101-6-798","article-title":"Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome","volume":"101","author":"Lokich","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0620","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7326\/0003-4819-97-1-61","article-title":"Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia","volume":"97","author":"Burgdorf","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0625","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/archderm.143.1.67","article-title":"Intertriginous eruption associated with chemotherapy in pediatric patients","volume":"143","author":"Webber","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0630","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0277-5379(90)90102-Y","article-title":"Erythema and swelling of ears after treatment with cytarabine for leukemia","volume":"26","author":"Krulder","year":"1990","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0635","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0190-9622(84)70210-6","article-title":"Neutrophilic eccrine hidradenitis: a distinctive rash associated with cytarabine therapy and acute leukemia","volume":"11","author":"Flynn","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0640","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1001\/archderm.126.1.73","article-title":"Eccrine squamous syringometaplasia. A cutaneous sweat gland reaction in the histologic spectrum of 'chemotherapy-associated eccrine hidradenitis' and 'neutrophilic eccrine hidradenitis.","volume":"126","author":"Hurt","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0645","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1001\/archderm.133.7.873","article-title":"Chemotherapy-induced eccrine squamous syringometaplasia. A distinctive eruption in patients receiving hematopoietic progenitor cells","volume":"133","author":"Valks","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0650","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1034\/j.1600-0560.2003.00113.x","article-title":"Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin","volume":"30","author":"English","year":"2003","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0655","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0190-9622(00)70293-3","article-title":"A case of cutaneous reaction to chemotherapeutic agents showing epidermal dysmaturation","volume":"43","author":"Chun","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0660","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1046\/j.1365-2230.1999.00419.x","article-title":"Chemotherapy-induced acral erythema (CIAE) with bullous reaction","volume":"24","author":"Azurdia","year":"1999","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0665","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archderm.129.1.43b","article-title":"Bullous variant of chemotherapy-induced acral erythema","volume":"129","author":"Waltzer","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0670","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archderm.133.7.905","article-title":"Antineoplastic chemotherapy, sweat, and the skin","volume":"133","author":"Horn","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0675","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1196\/annals.1422.019","article-title":"Drug-induced lupus","volume":"1108","author":"Borchers","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0680","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jaad.2007.06.040","article-title":"Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine","volume":"59","author":"Weger","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0685","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1111\/j.1365-2230.2009.03280.x","article-title":"Subacute cutaneous lupus erythematosus induced by capecitabine","volume":"34","author":"Floristan","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0690","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1001\/archdermatol.2008.619","article-title":"Subacute cutaneous lupus erythematosus associated with capecitabine monotherapy","volume":"145","author":"Fernandes","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0695","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1177\/0961203309103050","article-title":"Chemotherapy-induced subacute lupus erythematosus","volume":"18","author":"Guhl","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0700","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archdermatol.2010.258","article-title":"Subacute cutaneous lupus erythematosus exacerbated or induced by chemotherapy","volume":"146","author":"Funke","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0705","first-page":"818","article-title":"Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases","volume":"31","author":"Chen","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0710","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00384-008-0462-8","article-title":"Discoid lupus erythematosus (DLE)-like lesions induced by capecitabine","volume":"23","author":"Merlin","year":"2008","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.clindermatol.2011.08.032_bb0715","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.autrev.2004.10.003","article-title":"Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings","volume":"4","author":"Sontheimer","year":"2005","journal-title":"Autoimmun Rev"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X11002367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X11002367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T22:46:27Z","timestamp":1713048387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X11002367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":143,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0738081X11002367"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2011.08.032","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}